Tag: renal denervation

Otsuka Medical Devices and ReCor Medical submit pre-market approval of Paradise...

  Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing of the pre-market approval (PMA) application to the US Food and Drug...

ReCor Medical announces consistent reduction of blood pressure in pooled analysis...

ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significant blood pressure-lowering results across a range of patients with uncontrolled hypertension,...

SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other...

Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The late-breaking data were presented at the...

TCT 2022 hears “important data” from renal denervation trials

Findings from the RADIANCE II randomised pivotal trial, presented at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September, Boston, USA), “confirm that ultrasound...
ultrasound renal denervation

Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study

ReCor Medical and Otsuka Medical Devices have announced that the RADIANCE II US Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial...

SoniVie announces successful procedure with Tivus system on first patient enrolled...

SoniVie today announced that on 30 May this year the first patient was treated with its renal artery denervation Tivus therapeutic intravascular ultrasound technology, as...

SoniVie receives FDA IDE approval for pilot study to treat hypertension...

SoniVie recently announced that on 5 May 2022 the US Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its REDUCED1...

SyMap Medical completes enrolment of SMART study for treatment of uncontrolled...

SyMap Medical has announced that it has completed enrolment of the SMART study, which will evaluate the safety and efficacy of targeted renal denervation...

SyMap Medical closes US$100 million financing round

SyMap Medical has announced the completion of a financing round that will be used to accelerate global clinical trials for the company’s renal mapping...

TCT 2021: Six-month RADIANCE-HTN TRIO results “open a window” for renal...

Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasound renal denervation to a sham procedure for treatment-resistant hypertension, demonstrate the additional effects...

Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study

Medtronic today announced findings from a new study of patient preferences for the treatment of hypertension. The findings are set to be presented during...

SCAI releases proceedings from expert consensus roundtable on renal denervation treatment...

The Society for Cardiovascular Angiography and Interventions (SCAI) has released a proceedings document outlining the possible role of renal denervation (RDN) as a therapeutic...
denervation

Multi-organ denervation to combat cardiometabolic disease: A novel concept put to...

Following a successful proof-of-concept study, Gerard S Goh and Markus P Schlaich have embarked upon a first-in-human study to explore the safety and efficacy...
ultrasound renal denervation

ACC.21: Ultrasound renal denervation shown to reduce blood pressure in resistant...

Ultrasound-based endovascular renal denervation can successfully reduce systolic blood pressure in patients with medication-resistant hypertension, as demonstrated by the results of a late-breaking clinical...

EuroPCR 2021: Late-breaking data demonstrate long-term benefits of Medtronic radiofrequency renal...

Medtronic today announced new clinical data from the Global SYMPLICITY registry (GSR) indicating that renal denervation with the Medtronic Symplicity renal denervation system was...
metavention modus study

Metavention announces initiation of “groundbreaking” multi-organ denervation study

Metavention, a Minneapolis-headquartered medical device company, has announced the initiation of the MODUS study to treat patients with both type 2 diabetes and hypertension...
brattea renal denervation

Renal denervation firm Brattea completes US$20 million Series B+ funding round

Shanghai-based renal denervation (RDN) company Brattea has announced the successful completion of a Series B+ funding round worth more than US$20 million led by...